Zevra Therapeutics, Inc. (ZVRA)
10.13
+0.08
(+0.75%)
USD |
NASDAQ |
Oct 28, 12:29
Zevra Therapeutics Enterprise Value : 376.61M for Oct. 27, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 27, 2026 | 376.61M |
| October 26, 2026 | 345.45M |
| October 23, 2026 | 362.07M |
| October 22, 2026 | 392.93M |
| October 21, 2026 | 394.71M |
| October 20, 2026 | 401.24M |
| October 19, 2026 | 382.84M |
| October 16, 2026 | 369.78M |
| October 15, 2026 | 389.37M |
| October 14, 2026 | 386.99M |
| October 13, 2026 | 396.49M |
| October 12, 2026 | 451.68M |
| October 09, 2026 | 455.83M |
| October 08, 2026 | 432.69M |
| October 07, 2026 | 437.43M |
| October 06, 2026 | 416.66M |
| October 05, 2026 | 414.88M |
| October 02, 2026 | 372.75M |
| October 01, 2026 | 384.03M |
| September 30, 2026 | 430.91M |
| September 29, 2026 | 452.86M |
| September 28, 2026 | 450.49M |
| September 25, 2026 | 435.06M |
| September 24, 2026 | 448.12M |
| September 23, 2026 | 451.68M |
| Date | Value |
|---|---|
| September 22, 2026 | 467.11M |
| September 21, 2026 | 472.45M |
| September 18, 2026 | 468.89M |
| September 17, 2026 | 482.53M |
| September 16, 2026 | 480.16M |
| September 15, 2026 | 471.26M |
| September 14, 2026 | 495.00M |
| September 11, 2026 | 492.62M |
| September 10, 2026 | 495.59M |
| September 09, 2026 | 494.40M |
| September 08, 2026 | 532.08M |
| September 04, 2026 | 515.77M |
| September 03, 2026 | 524.07M |
| September 02, 2026 | 509.83M |
| September 01, 2026 | 495.59M |
| August 31, 2026 | 476.60M |
| August 28, 2026 | 466.22M |
| August 27, 2026 | 483.13M |
| August 26, 2026 | 476.60M |
| August 25, 2026 | 494.40M |
| August 24, 2026 | 471.26M |
| August 21, 2026 | 484.31M |
| August 20, 2026 | 485.50M |
| August 19, 2026 | 499.74M |
| August 18, 2026 | 466.51M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Innoviva, Inc. | 1.212B |
| Xeris Biopharma Holdings, Inc. | 1.982B |
| ANI Pharmaceuticals, Inc. | 1.870B |
| Corcept Therapeutics, Inc. | 9.154B |
| Veru, Inc. | 15.77M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 8.393M |
| Revenue (Quarterly) | 39.66M |
| Total Expenses (Quarterly) | 31.27M |
| EPS Diluted (Quarterly) | 0.1368 |
| Gross Profit Margin (Quarterly) | 95.36% |
| Profit Margin (Quarterly) | 21.16% |
| Earnings Yield | 9.15% |
| Operating Earnings Yield | 6.49% |
| Normalized Earnings Yield | 11.20 |